News & Updates
Filter by Specialty:
Chronic constipation not a risk factor for later colorectal cancer
Individuals with chronic constipation do not seem to be at increased risk of developing subsequent colorectal cancer as compared with their peers who do not have the gastrointestinal condition, as reported in a study.
Chronic constipation not a risk factor for later colorectal cancer
27 Oct 2021
Durvalumab + tremelimumab + chemo: A new first-line SoC for mNSCLC?
The combination of durvalumab, tremelimumab, and chemotherapy in the first-line setting improved progression-free survival (PFS) and overall survival (OS) in patients with metastatic non-small-cell lung cancer (mNSCLC), according to results of the phase III POSEIDON trial.
Durvalumab + tremelimumab + chemo: A new first-line SoC for mNSCLC?
26 Oct 2021
Everolimus helps fight recurrent thymic neuroendocrine neoplasia
Treatment with everolimus appears to have beneficial effects on recurrent thymic neuroendocrine neoplasia (NEN), particularly well-differentiated tumours, with patients having a low Ki-67 index more likely to have a better outcome with the drug, as shown in a small study.
Everolimus helps fight recurrent thymic neuroendocrine neoplasia
26 Oct 2021
Minimally invasive surgery feasible for nonendometroid endometrial cancers
Minimally invasive surgery for nonendometrioid endometrial cancer performs comparably as open surgery, yielding similar survival outcomes, a recent study has found.
Minimally invasive surgery feasible for nonendometroid endometrial cancers
26 Oct 2021
Dose-capping chemoradiotherapy tied to higher recurrence in rectal cancer
The risk of disease recurrence is increased among rectal cancer patients treated with dose-capped chemoradiotherapy (CRT), reveals a study. In addition, excessive toxicity has occurred among those dosed by actual body surface area (BSA) compared to patients in the dose-capped group.